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by the same method, where a similar 
safety profi le has been seen after >15 
million vaccinations in humans.
This is the fi rst study that reports 
that an inactivated whole virus vaccine 
with an aluminum phosphate adjuvant 
system against infl uenza A (H5N1) 
was safe and immunogenic in humans 
after only 1 injection. This study re-
ports the lowest effective dose used 
to cause immune response. Other tri-
als used much higher maximum doses 
and required 2 injections 21 or 28 days 
apart (8–10). Using the lowest possi-
ble amount of the antigen and fewer 
injections is essential for increasing 
the production capacity of vaccine 
manufacturers in a pandemic (2).
Using 1, instead of 2, injections 
will shorten the time needed to devel-
op immune response by 3–4 weeks. 
Unlike previous studies on infl uenza 
A (H5N1) vaccines that reported only 
data from 21, 28, or 56 days after the 
fi nal vaccination (8–10), we report 
data up to 90 days. The lower dose 
and fewer injections required to trig-
ger an immune response can be at 
least partially explained by using a 
whole virus vaccine and an aluminum 
phosphate adjuvant system. The use 
of a different adjuvant system than 
ours may have infl uenced the results 
of other trials (9,10). Other investiga-
tors used a modifi ed HI method with 
horse erythrocytes, which are known 
to be more sensitive for infl uenza A 
(H5N1) subtype than the convention-
ally used turkey or chicken erythro-
cytes (8,9). Thus, if horse erythro-
cytes had been used in our study, the 
vaccine would likely have been even 
more immunogenic.
This study found fewer, less fre-
quent, and milder side effects than 
did other trials of infl uenza A (H5N1) 
vaccines published so far (8–10). 
This could possibly be explained by 
the smaller dose used. Also, the en-
dotoxin content of 0.1 IU/mL in our 
vaccine was much smaller then the 
allowed amount of 100 IU/mL by 
standards (5).
We report an inactivated whole 
virus vaccine that is safe and immu-
nogenic in healthy adults and that re-
quires a low dose and only 1 injection 
to trigger an immune response. We are 
conducting trials in elderly persons 
and children.
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To the Editor: The title of the let-
ter by Cojean et al. (1) is misleading. 
The data presented essentially point to 
an absence of in vitro resistance to di-
hydroartemisinin (dhART) in the pan-
el of African isolates studied, with 1 of 
397 isolates having an elevated 50% 
inhibitory concentration (IC50) for 
dhART. The S769N PfATPase6 muta-
tion associated with in vitro resistance 
to artemether (2) was observed in 1 
isolate. This mutant isolate had a low 
IC50 for dhART, but its IC50 for arte-
mether has not been tested. Since the 
relationship between in vitro suscepti-
bility to artemether and dhART is still 
uncertain (3), these data do not dis-
prove the association of a PfATPase6 
S769N polymorphism with elevated 
IC50 for artemether that was observed 
in isolates from French Guiana (2).
Worth noting is that the associa-
tion of the S769N PfATPase6 poly-
morphism with elevated IC50 for arte-
mether was confi rmed in an isolate 
collected in French Guiana in 2005; 
that isolate had an IC50 for artemether 
of 127 nmol/L. Molecular typing iden-
tifi ed 2 clonal types, 1 with a wild-type 
PfATPase6 allele and 1 with a S769N 
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single mutant. After 3 weeks of in vi-
tro cultivation without drug, the mu-
tant allele was no longer detected and 
the IC50 for artemether was 8.2 nmol/
L. This fi nding suggests poor fi tness of 
the mutant allele under standard cul-
ture conditions.
The observation of an additional 
case of in vitro resistance to arte-
mether in French Guiana 3 years after 
the fi rst cases is of concern. Reinforce-
ment of surveillance is needed as is 
clarifi cation of the relationship of in 
vitro susceptibility to artemether and 
artesunate, the derivatives currently 
included in artemisinin-based combi-
nation therapies (ACTs). Surveillance 
and clarifi cation would be particularly 
timely since emerging clinical or para-
sitologic failures to some ACTs have 
been reported (4,5).
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In Response: The original title 
of our article was “Lack of Plasmodi-
um falciparum in Vitro and Genomic 
Resistance to Dihydroartemisinin in 
Travelers Returning to France from 
Africa.” EID’s shortening of the title 
(1) led to the perception that the let-
ter title was misleading, but it was not 
on purpose. We have recently tested 
the 50% inhibitory concentration for 
artemether of the S769N PfATPase6 
isolate that we had kept in liquid nitro-
gen, and it showed susceptibility.
We underline that the previous-
ly reported clinical or parasitologic 
failures to some artemisinin-based 
combination therapies (2,3) were not 
synonymous with the emergence of 
resistance to artemisinin compounds. 
In the study by Grandesso et al., a 
combination of artesunate plus amodi-
aquine was given to children <5 years 
of age who lived in an area in which 
amodiaquine alone was ineffective to 
adequately treat uncomplicated falci-
parum malaria in 1 of 3 cases at day 
28 (2). Such a combination (artesunate 
plus amodiaquine) was nearly equiva-
lent in 1 of 3 cases to a 3-day artesu-
nate monotherapy, which may fail to 
completely cure children because of 
the short half-life of artesunate. In 
the study by Bukirwa et al., no recru-
descence occurred in patients treated 
with artesunate plus amodiaquine and 
only 2 of 199 patients treated with 
artemether plus lumefantrine experi-
enced recrudescence at day 28 (3). As 
Birkiwa et al. themselves acknowl-
edged, artemether plus lumefantrine 
was not administered with food, and 
it is known that lumefantrine is ab-
sorbed better when it is taken with a 
small amount of fat. Thus, the clinical 
failures observed did not necessarily 
refl ect P. falciparum resistance to ar-
temisinin compounds.
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